Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection: Clinical dermatology • Concise report

Clinical and Experimental Dermatology

Volumn 35, Issue 4, 2010, Pages 397-398

  Behnam, S E ^a   Hindiyeh, R ^a   Fife, D J ^b   Jeffes III, E W ^a   Wu, J J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CALCIPOTRIOL; ETANERCEPT; ETRETIN; FLUOCINONIDE; LIVER ENZYME; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DISEASE EXACERBATION; DRUG INDICATION; DRUG TOLERANCE; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PSORIASIS; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RIBAVIRIN;

EID: 77951237063     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03476.x     Document Type: Article

References (6)

1. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 2000 25 : 351 352. (Pubitemid 30670597)
2. De Simone C, Paradisi A, Capizzi R et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006 54 : 1102 1104. (Pubitemid 43732395)
3. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection. Report of 3 cases. J Am Acad Dermatol 2004 51 : 580 584.
4. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003 14 : 229 232. (Pubitemid 37474535)
5. Marotte H, Fontanges E, Bailly F et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007 46 : 97 9. (Pubitemid 44932794)
6. Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005 42 : 315 322.